Migranal (Dihydroergotamine Mesilate)

Dihydroergotamine mesilate acts as a partial agonist at serotonin 5‑HT1 receptors and blocks alpha‑adrenergic and dopaminergic receptors. This results in constriction of intracranial blood vessels and suppression of neurogenic inflammation, which together abort migraine episodes.

The prescribed dose of Migranal is determined by the treating physician. Each spray delivers 1 mg of dihydroergotamine mesilate, and the number of sprays per migraine attack is individualized based on clinical response and tolerability.

Safety of dihydroergotamine mesilate during pregnancy or lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the prescriber must evaluate each case carefully.

To order Migranal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with triptans, dihydroergotamine offers a non‑triptan abortive option that can be effective in patients who do not respond to or cannot take triptans. Its nasal spray formulation provides rapid absorption, but it carries a distinct vasoconstrictive side‑effect profile that requires careful patient selection.

Store Migranal nasal spray below 25 °C in its original packaging. Protect the device from moisture, heat and direct sunlight. Do not freeze the product, and keep the spray cap tightly closed when not in use.

Migranal is given intranasally. The patient tilts the head slightly forward, inserts the nozzle into one nostril, and actuates the pump to deliver a single spray (1 mg). The dose may be repeated as directed by the prescriber, typically with a minimum interval between sprays.

Serious adverse events include severe vasoconstriction leading to hypertension, myocardial or peripheral ischemia, rare cases of serotonin syndrome, and anaphylaxis. Patients should seek immediate medical attention if they experience chest pain, severe headache, visual changes, or signs of an allergic reaction.

Migranal is contraindicated in individuals with known hypersensitivity to ergot alkaloids, uncontrolled hypertension, coronary artery disease, peripheral vascular disease, severe hepatic impairment, or in patients currently taking monoamine oxidase inhibitors. It should also be avoided in pregnancy unless clearly needed.